Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06818721 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Intravitreal Topotecan for Prevention or Treatment of Proliferative Vitreoretinopathy in Retinal Detachment

Study acronym: TOPO-PT
StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary endpoint revised Primary and study completion dates: Mar 2027 to Apr 2027 · Start date: Feb 2025 to Mar 2025 · Secondary endpoints revised (6) · 2 morev2 Show 5 more changesShow less
    • Primary and study completion dates: Mar 2027 to Apr 2027
    • Start date: Feb 2025 to Mar 2025
    • Secondary endpoints revised (6)
    • Study description expanded, about 123 words
    • Study title shortened, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Intravitreal topotecan exhibits strong anti-inflammatory, anti-proliferative, and anti-fibrotic properties, making it a promising option for preventing and treating proliferative vitreoretinopathy in rhegmatogenous retinal detachment. Preclinical studies have demonstrated its efficacy in proliferative vitreoretinopathy models, where no adverse events have been reported for doses of 5 µg to 30 µg. This prospective, matched cohort study aims to assess the therapeutic efficacy and safety of intravitreal topotecan for preventing and treating proliferative vitreoretinopathy in rhegmatogenous retinal detachment patients.
Trial Details
NCT Number NCT06818721
Lead Sponsor Unity Health Toronto
Conditions Retinal Detachment Rhegmatogenous, Proliferative Vitreoretinopathy
Enrollment 394 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov